Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AC Immune (ACIU) Current Deferred Revenue (2016 - 2024)

Historic Current Deferred Revenue for AC Immune (ACIU) over the last 11 years, with Q4 2024 value amounting to $97.1 million.

  • AC Immune's Current Deferred Revenue fell 3759.07% to $97.1 million in Q4 2024 from the same period last year, while for Dec 2024 it was $97.1 million, marking a year-over-year decrease of 3759.07%. This contributed to the annual value of $97.1 million for FY2024, which is 3759.07% down from last year.
  • According to the latest figures from Q4 2024, AC Immune's Current Deferred Revenue is $97.1 million, which was down 3759.07% from $18467.3 recorded in Q3 2024.
  • AC Immune's Current Deferred Revenue's 5-year high stood at $777.6 million during Q4 2021, with a 5-year trough of $18467.3 in Q3 2024.
  • For the 5-year period, AC Immune's Current Deferred Revenue averaged around $109.8 million, with its median value being $575949.0 (2022).
  • Per our database at Business Quant, AC Immune's Current Deferred Revenue skyrocketed by 22962694.36% in 2021 and then plummeted by 9995.51% in 2022.
  • Quarter analysis of 5 years shows AC Immune's Current Deferred Revenue stood at $338483.6 in 2020, then skyrocketed by 229626.94% to $777.6 million in 2021, then crashed by 99.92% to $609318.8 in 2022, then surged by 25432.6% to $155.6 million in 2023, then plummeted by 37.59% to $97.1 million in 2024.
  • Its Current Deferred Revenue was $97.1 million in Q4 2024, compared to $18467.3 in Q3 2024 and $49760.7 in Q2 2024.